Bococizumab is a novel anti-PCSK9 antibody efficiently developed to treat hypercholesterolemia. Such therapeutic agent interacts with the PCSK9 protein, a critical regulator of cholesterol concentrations. By inhibiting https://gerardxqbr893053.mpeblog.com/73212596/bococizumab-a-novel-anti-pcsk9-antibody-for-hypercholesterolemia